Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
China300 participantsStarted 2026-05-01
Plain-language summary
This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients 18-80 of age.
✓. Patients undergo planned CABG for the first time with ≥1 SVGs
✓. Patients with written informed consent.
Exclusion criteria
✕. Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.
✕. Patients undergoing emergency CABG.
✕. Patients with single-vessel coronary artery disease.
✕. Patients with cardiogenic shock or hemodynamic instability.
✕. Patients with sick sinus syndrome, second- or third-degree atrioventricular block.
✕. Patients with contraindications for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.
✕. Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.